At Tuesday's close, Cingulate shares fell 4.99% to $3.62 and slipped further 1.66% to $3.56 in after-hours trading. According to the Kansas-based biotech, children who took CTx-1301 at doses of 18 ...

But this month, Cingulate was able to reinstate those executives’ annual base salaries. CEO Shane Schaffer’s annual base salary is back to $503,000, COO Laurie Myer’s salary is $424,000, and ...

Cingulate Inc. (NASDAQ:CING) shares are surging, trading over 159% higher today. Here’s what’s driving the movement. Why It’s Moving: Cingulate’s stock is soaring following the ...

Studies have shown a particular part of the brain, the cingulate gyrus, which is in the middle part of the brain, has been associated with severe forms of depression.Experiments have been done ...

It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301, which is designed to treat Attention Deficit Hyperactivity Disorder (ADHD).

The Kansas City, Kansas-based pharmaceutical startup has worked its way through a couple of delisting warnings from the Nasdaq stock exchange. Cingulate loses key execs, almost its entire board ...

KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its ...

The cingulate gyrus also helps with emotions, memory, and learning. It specifically links outcomes with behavior, allowing people to see the cause and effect of their actions.

Noninvasive modulation of subcallosal cingulate and depression with focused ultrasonic waves. Biological Psychiatry. 2024 Oct 11.doi: 10.1016/j.biopsych.2024.09.029 ...

Cingulate Inc. CING shares are surging, trading over 159% higher today. Here’s what’s driving the movement. Why It’s Moving: Cingulate’s stock is soaring following the announcement that ...